Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer

Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer

ObjectiveThe current clinical data regarding the re-administration of PARPi maintenance therapy in platinum sensitive recurrent ovarian cancer (PSROC) is limited. This study aims to investigate the efficacy and associated factors of PARPi re-maintenance therapy in PSROC patients in China.MethodsIn t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yulin Wang, Yunjie Yang, Binghong Guo, Xiaoyan Li, Renakezi Tuersun, Ye Cao, Jundong Li, Jihong Liu, Su Li, Tao Liu, Yongwen Huang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	recurrent ovarian cancer PARP inhibitors re-maintenance therapy prognosis structural domains of BRCA mutations
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1512339/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
by: О. N. Churuksaeva, et al.
Published: (2023-09-01)

The evolving role of PARP inhibitors in advanced ovarian cancer
by: Levva Sofia, et al.
Published: (2021-08-01)

High-Risk Factors and Therapeutic Advances in Ovarian Cancer
by: Xiaoyu SHA, et al.
Published: (2025-07-01)

A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer
by: A. B. Villert, et al.
Published: (2022-09-01)

Hereditary breast cancer and ovarian cancer: clinical course and treatment
by: V. V. Semiglazov, et al.
Published: (2021-03-01)

Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in <i>BRCA1/2</i>-Proficient Cancer Cells
by: Danyang Zhou, et al.
Published: (2025-04-01)

Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea
by: Hyeong In Ha, et al.
Published: (2024-10-01)

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
by: Whitney S Graybill, et al.
Published: (2024-12-01)

Hereditary breast and ovarian cancer syndrome (BRCA) gene: Concept, pathways, therapeutics, and future
by: Anup Tamhankar, et al.
Published: (2020-01-01)

Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion
by: Monique G.P. van der Wijst, et al.
Published: (2015-08-01)

Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
by: Theresa L. Werner, et al.
Published: (2018-06-01)

Retreatment with PARPi following stem cell transplant in a patient with recurrent ovarian cancer and myelodysplastic syndrome
by: Shilpa Mokshagundam, et al.
Published: (2025-08-01)

Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors
by: Romain Pacaud, et al.
Published: (2025-01-01)

Features and complexity of treatment of <i>BRCA</i>-associated ovarian cancer, chronic disease: literature review
by: T. V. Gorodnova, et al.
Published: (2024-11-01)

RISK FACTORS OF OVARIAN CANCER AND POSSIBLE PREVENTIVE STRATEGIES
by: OLGA B. Karelina, et al.
Published: (2018-09-01)

Comparative characteristics of the effectiveness of therapy with PARP inhibitor in patients with primary ovarian cancer in the Tyumen Region in the period from 2019 to 2023
by: M. Ya. Kuzmenko, et al.
Published: (2025-05-01)

Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment
by: Giovanni Luca Scaglione, et al.
Published: (2025-05-01)

First‐In‐Human Dose Finding Study of Venadaparib (IDX‐1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors
by: Sung‐Bae Kim, et al.
Published: (2025-02-01)

Diagnosis and treatment of ovarian cancer in the light of modern molecular genetic achievements
by: E. M. Kagirova, et al.
Published: (2023-11-01)

Genetic predisposition for ovarian cancer development
by: Joksić Ivana, et al.
Published: (2025-01-01)

A systematic review on the association between ovarian and prostate cancer with <I>BRCA1</I> and <I>BRCA2</I> gene
by: Sarpparajan Chitra Veena, et al.
Published: (2023-01-01)

Four-year recurrence-free survival in metastatic uterine adenosarcoma with somatic BRCA2 mutation on olaparib therapy: A case report
by: Katie Foug, et al.
Published: (2025-04-01)

Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients
by: Maria Delgado-Ortet, et al.
Published: (2025-06-01)

HELQ upregulates PARP1 to drive platinum resistance and predict therapeutic response in ovarian cancer
by: Shuran Tan, et al.
Published: (2025-07-01)

Recent Developments in Rare Ovarian Carcinosarcoma: Literature Review and Case Report
by: Alexandra Nienhaus, et al.
Published: (2025-05-01)

Cost-effectiveness analysis of population-based BRCA1/2 testing, family-history-based BRCA1/2 testing, and symptom-based screening for breast and ovarian cancer in China
by: Feilong Zhao, et al.
Published: (2025-06-01)

Research progress on ferroptosis and PARP inhibitors in ovarian cancer: action mechanisms and resistance mechanisms
by: Jiqing Zhang, et al.
Published: (2025-04-01)

CLINICAL AND MORPHOLOGICAL FEATURES OF HEREDITARY OVARIAN CANCER
by: K. B. Kotiv, et al.
Published: (2017-12-01)

Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers
by: Anna Sokolenko, et al.
Published: (2025-06-01)

Role of KLF5 in enhancing ovarian cancer stemness and PARPi resistance: mechanisms and therapeutic targeting
by: Huimin Xiao, et al.
Published: (2025-04-01)

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies
by: Shant Apelian, et al.
Published: (2025-05-01)

Mutational spectrum and profile of breast and ovarian cancer patients in Saudi Arabia’s western region: single center experience
by: Samar N. Ekram, et al.
Published: (2025-05-01)

Causative Genes of Homologous Recombination Deficiency (HRD)-Related Breast Cancer and Specific Strategies at Present
by: Seigo Nakamura, et al.
Published: (2025-02-01)

HEREDITARY BREAST CANCER
by: E. M. Bit-Sava, et al.
Published: (2016-02-01)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
by: Marta Castroviejo‐Bermejo, et al.
Published: (2018-10-01)

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
by: Anna D. Staniszewska, et al.
Published: (2022-12-01)

REPEATED OPTIMAL CYTOREDUCTIVE SURGERIES IN COMBINED MODALITY TREATMENT OF OVARIAN CANCER. CASE REPORT
by: S. V. Molchanov, et al.
Published: (2017-07-01)

Bevacizumab in maintenance therapy for ovarian cancer patients
by: L. Yu. Vladimirova, et al.
Published: (2020-08-01)

Multimodal data integration with machine learning for predicting PARP inhibitor efficacy and prognosis in ovarian cancer
by: Xi’an Xiong, et al.
Published: (2025-06-01)